Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Oct. 31, 2016
Oct. 31, 2015
Revenues:    
Clinical laboratory services $ 18,558 $ 17,090
Product revenues 7,426 7,687
Royalty and license fee income 300 400
Total revenues 26,284 25,177
Operating costs, expenses and legal settlements, net:    
Cost of clinical laboratory services 10,896 10,332
Cost of product revenues 3,309 3,611
Research and development 822 867
Selling, general, and administrative 11,474 10,225
Provision for uncollectible accounts receivable 669 704
Legal fee expense 372 1,601
Legal settlements, net   (6,800)
Total operating costs, expenses and legal settlements, net 27,542 20,540
Operating (loss) income (1,258) 4,637
Other income (expense):    
Interest 46 (40)
Other 119 54
Foreign exchange loss (361) (130)
(Loss) income before income taxes (1,454) 4,521
Provision for income taxes (20) (87)
Net (loss) income $ (1,474) $ 4,434
Net (loss) income per common share:    
Basic (in Dollars per share) $ (0.03) $ 0.10
Diluted (in Dollars per share) $ (0.03) $ 0.10
Weighted average common shares outstanding:    
Basic (in Shares) 46,272 46,068
Diluted (in Shares) 46,272 46,193